Vaccine Choice Canada

Your Child. Your Future. Your Choice.

Donate Button
  • About Vaccines
    • Vaccination: Basic Concerns
      • Children’s Health in Decline
      • Contraindications to Vaccination
      • Parent’s Guide to Vaccination
      • Adverse Events – Unreported
      • Disease Trends
    • General Issues
      • Informed Consent – Mature Minor – Ethics
      • Politics of Vaccination
      • Healthcare Worker & Student Vaccines
      • Herd Immunity
      • Doctors Speak
      • Parents Speak
      • Reports
    • Specific Vaccines
    • Vaccine Ingredients
  • Health Risks
  • Science
  • Exemptions
    • Legal Exemption Forms
    • Canadian Medical Law
    • Ontario Daycare Exemptions
    • Immunization Not Mandatory in Canada
    • Threats to Exemptions
    • Take Action / Events
  • Personal Stories
  • Alternatives
    • Alternatives – Specific Infections
  • Articles
  • Resources
    • Child Health Links
    • Pro-vaccine websites
    • Video & Audio
  • Home
  • About VCC
    • Policy Statement on Vaccination
    • Who We Are & What We Do
    • VCC History
    • Privacy Policy
    • Disclaimer
  • Join
  • Report a Reaction
  • Bookstore
  • Contact
  • Member’s Area
    • Journal Archive
  • Site Map
  • Media
You are here: Home / Specific Vaccines / Influenza Vaccine / ID Biomedical Provides Update on Vaccine Development Programs

ID Biomedical Provides Update on Vaccine Development Programs

April 7, 2009 By Vaccine Choice Canada

  • Clinical testing of FluINsure in children has begun
  • Clinical testing of StreptAvax to be postponed

Vancouver, BC — October 24, 2005 — ID Biomedical Corporation (TSX: IDB; NASDAQ: IDBE) today provided an update on two of its lead vaccines in clinical development: FluINsure™, a non-living intranasally delivered influenza vaccine, and StreptAvax™, a subunit protein-based vaccine against group A streptococcal diseases.

ID Biomedical announced that it has obtained clearance from Health Canada to begin the first pediatric study of the FluINsure vaccine. This Phase II study will be conducted at three centers in Canada in 160 healthy children, aged 3 to 12 years old. The study will be blinded, randomized, and placebo-controlled and will evaluate safety and immunogenicity of one-dose and two-dose regimens of the vaccine. Enrollment for the study has begun.

The Company also announced that it recently held a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) regarding the pediatric development program for its StreptAvax vaccine. At the pre-IND meeting, the FDA asked the Company to provide a significant amount of additional information and follow-up from the recently completed adult study prior to further considering initiation of studies in children. At this time, ID Biomedical is not able to precisely predict how long it may take to generate this data and to what extent additional testing and follow up in adults may be required before obtaining approval to conduct studies in children. Based on a preliminary assessment of the nature and the amount of information requested by the FDA, the Company does not currently expect to begin testing the vaccine in children in the U.S. prior to 2007. The Company expects additional dialogue with the FDA regarding the requirements for continuing development of the vaccine candidate.

About ID Biomedical

ID Biomedical is an integrated biotechnology company dedicated to the development of innovative vaccine products. It operates in research, development, manufacturing, sales and marketing from its facilities in Canada and in the United States. ID Biomedical is dedicated to becoming a premier vaccine company with significant marketed products worldwide and an extensive pipeline in both clinical and preclinical development.

ID Biomedical has a leading position in the Canadian influenza market. It received a ten-year mandate from the Government of Canada in 2001 to assure a state of readiness in the case of an influenza pandemic and provide influenza vaccine for all Canadians in such an event. It also currently supplies approximately 75% of the Canadian government’s influenza vaccine purchases.

On September 7, 2005, ID Biomedical announced an agreement for GlaxoSmithKline to acquire ID Biomedical. The acquisition, which has been approved unanimously by both GlaxoSmithKline and ID Biomedical’s Boards of Directors, is subject to the approval of ID Biomedical’s shareholders, applicable regulatory clearances and certain other conditions. The transaction is expected to close by the end of 2005 or early 2006.

For further information on ID Biomedical, please visit the Company’s website at www.idbiomedical.com.

The information in this news release contains so-called “forward-looking” statements. These include statements regarding ID Biomedical’s expectations and plans relating to the integration of the vaccine business acquired from Shire, statements about ID Biomedical’s expectations, beliefs, intentions or strategies for the future, which may be indicated by words or phrases such as “anticipate”, “expect”, “intend”, “plan”, “will”, “we believe”, “ID Biomedical believes”, “management believes”, and similar language. All forward-looking statements are based on ID Biomedical’s current expectations and are subject to risks and uncertainties and to assumptions made. Important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) the company’s ability to successfully complete preclinical and clinical development of its products; (ii) the company’s ability to manufacture its products; (iii) the seasonality of the flu-vaccine business and related fluctuations in the company’s revenues from quarter to quarter; (iv) decisions, and the timing of decisions, made by the health regulatory agencies regarding approval of its products for human testing; (v) the company’s ability to enter into distribution agreements for its products, and to complete and maintain corporate alliances relating to the development and commercialization of its technology and products; (vi) market acceptance of its technologies and products; and (vii) the competitive environment and impact of technological change and other risks detailed in the company’s filings with the Securities and Exchange Commission. ID Biomedical bases its forward-looking statements on information currently available to it, and assumes no obligation to update them.

Share this:

Filed Under: Influenza Vaccine, Specific Vaccines Tagged With: Flu Vaccine, Influenza Vaccine

Articles by Category

  • About Vaccines
    (178)
    • Adverse Events
      (106)
    • Compensation
      (5)
    • Contraindications
      (1)
    • Herd Immunity
      (11)
    • Informed Consent – Mature Minor – Ethics
      (80)
    • Reports
      (13)
  • Disease Trends
    (27)
  • Doctors Speak
    (54)
  • Exemptions
    (164)
    • Take Action
      (108)
    • Threats to Exemptions
      (147)
  • Health Risks
    (147)
    • Anaphylaxis, Allergies, and Asthma
      (26)
    • Autism
      (55)
    • Brain and Neurological Injuries
      (37)
    • Cancer
      (3)
    • Decline in Children's Health
      (26)
    • Gulf War Syndrome
      (4)
    • Infertility
      (1)
    • Obesity and Diabetes
      (4)
    • Pregnancy – Risks to the Foetus
      (5)
    • SIDS-SBS
      (12)
  • Media
    (82)
  • Parents Speak
    (32)
  • Personal Stories
    (28)
  • Politics of Vaccination
    (39)
  • Resources
    (57)
    • Books & Periodicals
      (1)
    • PDF files
      (3)
    • Videos
      (0)
  • Specific Vaccines
    (223)
    • Chickenpox and Shingles Vaccines
      (12)
    • COVID-19 Vaccine
      (5)
    • Diphtheria, Tetanus, Pertussis, and Hib Vaccine
      (38)
    • Healthcare Worker & Student Vaccines
      (15)
    • Hepatitis-B Vaccine
      (20)
    • HPV Vaccine
      (19)
    • Influenza Vaccine
      (46)
    • Measles, Mumps, & Rubella Vaccine
      (47)
    • Meningococcal Disease Vaccine
      (9)
    • Pet Vaccines
      (1)
    • Pneumococcal Disease Vaccine
      (4)
    • Polio Vaccine
      (13)
    • Rotavirus Vaccine
      (1)
    • Smallpox Vaccine
      (4)
    • Travel Vaccines
      (1)
  • Vaccine Alternatives
    (13)
    • Vaccine Alternatives – General
      (7)
    • Vaccine Alternatives – Specific Infections
      (6)
  • Vaccine Ingredients
    (69)
    • Aluminum
      (23)
    • Biological Ingredients
      (15)
    • Chemical Ingredients
      (15)
    • Food Allergens
      (4)
    • Mercury
      (24)
    • Oil-based Adjuvants
      (11)

Join Vaccine Choice Canada

To support our educational and outreach work , please join Vaccine Choice Canada today. Sign Me Up!

Log In


Lost your password?

About Vaccine Choice Canada

Vaccine Choice Canada is a volunteer run, federally registered … read more

Our Mission

Vaccine Choice Canada (formerly VRAN) continues the work of … more

Disclaimer

The contents of this website are for informational purposes … more

Vaccine Choice Canada logo

Find More on

  • Decline in Children's Health
    (26)
  • Doctors Speak
    (54)
  • Exemptions
    (129)
  • Health Risks
    (39)
  • Parents Speak
    (32)
  • Personal Stories
    (28)
  • Resources
    (56)
  • Specific Vaccines
    (92)
  • Vaccine Alternatives
    (8)
  • Vaccine Ingredients
    (22)

Personal Stories

Susan’s Flu Vaccine Reaction

In 2013, I contracted the H1N1 strain of flu.  I was deathly … [Read More...]

My Journey with Vaccine Awareness and a closer look at Vaxxed vs. Unvaxxed

I was born in the mid 1980’s and was fully vaccinated as a … [Read More...]

A story of my grandson’s visit, discovery of his autism, and how he recovered

By Shanna Mi    November 2019 It was a glorious late … [Read More...]

Laura’s Story

July 2002 Today is my daughter's sweet 16th birthday but … [Read More...]

More Personal Stories

Featured Articles

Top Picks January 2021

January 5, 2021 FEATURES Measures do not prevent deaths, … [Read More...]

Dear Family, Friends and Colleagues Re COVID-19 Vaccine Concerns

Dear Family, Friends and Colleagues Re: COVID-19 Vaccine … [Read More...]

Dear Police, Healthcare Workers, and First Responders Re COVID-19 Vaccine Concerns

January 5, 2021 Dear Police, First Responders and … [Read More...]

Questioning the COVID Narrative & Measures

Medical Professionals/Researchers Open Letter to Dr. … [Read More...]

More News Articles

Copyright © 2021 Vaccine Choice Canada